224 related articles for article (PubMed ID: 12966450)
41. Cost-effectiveness of apixaban for prevention of venous thromboembolic events in patients after gynecologic cancer surgery.
Glickman A; Brennecke A; Tayebnejad A; Matsuo K; Guntupalli SR; Sheeder J
Gynecol Oncol; 2020 Nov; 159(2):476-482. PubMed ID: 32854972
[TBL] [Abstract][Full Text] [Related]
42. [Evidence for thrombosis prophylaxis to high-risk patients].
Själander A; Jansson JH; Bergqvist D; Eriksson H; Svensson P
Lakartidningen; 2007 May 14-29; 104(20-21):1585-7. PubMed ID: 17564265
[No Abstract] [Full Text] [Related]
43. Low-molecular-weight heparins in clinical practice.
Hunt D
South Med J; 1998 Jan; 91(1):2-10. PubMed ID: 9438394
[TBL] [Abstract][Full Text] [Related]
44. Optimal dosing of bemiparin as prophylaxis against venous thromboembolism in surgery for cancer: an audit of practice.
Balibrea JL; Altimiras J; Larruzea I; Gómez-Outes A; Martínez-González J; Rocha E;
Int J Surg; 2007 Apr; 5(2):114-9. PubMed ID: 17448976
[TBL] [Abstract][Full Text] [Related]
45. Cost utility of substituting enoxaparin for unfractionated heparin for prophylaxis of venous thrombosis in the hospitalized medical patient.
Leykum L; Pugh J; Diuguid D; Papadopoulos K
J Hosp Med; 2006 May; 1(3):168-76. PubMed ID: 17219491
[TBL] [Abstract][Full Text] [Related]
46. [Thrombosis prophylaxis in orthopedic surgery].
Finsen V
Tidsskr Nor Laegeforen; 2000 Feb; 120(5):565-7. PubMed ID: 10833913
[TBL] [Abstract][Full Text] [Related]
47. Cost analysis of fondaparinux versus enoxaparin as venous thromboembolism prophylaxis in elective hip replacement surgery.
Spruill WJ; Wade WE; Leslie RB
Blood Coagul Fibrinolysis; 2004 Oct; 15(7):539-43. PubMed ID: 15389119
[TBL] [Abstract][Full Text] [Related]
48. Cost analysis of ardeparin versus enoxaparin for the prophylaxis of deep vein thrombosis after knee arthroplasty.
Wade WE
Clin Ther; 1998; 20(2):347-51. PubMed ID: 9589825
[TBL] [Abstract][Full Text] [Related]
49. Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: a single technology appraisal.
Holmes M; Carroll C; Papaioannou D
Health Technol Assess; 2009 Sep; 13 Suppl 2():55-62. PubMed ID: 19804690
[TBL] [Abstract][Full Text] [Related]
50. Routine Use of Low-Molecular-Weight Heparin For Deep Venous Thrombosis Prophylaxis After Foot and Ankle Surgery: A Cost-Effectiveness Analysis.
Robinson R; Wirt TC; Barbosa C; Amidi A; Chen S; Joseph RM; Fleischer AE
J Foot Ankle Surg; 2018; 57(3):543-551. PubMed ID: 29685566
[TBL] [Abstract][Full Text] [Related]
51. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.
Stevenson M; Scope A; Holmes M; Rees A; Kaltenthaler E
Health Technol Assess; 2009 Oct; 13 Suppl 3():43-8. PubMed ID: 19846028
[TBL] [Abstract][Full Text] [Related]
52. Gold Medal Forum Winner. Unfractionated heparin three times a day versus enoxaparin in the prevention of deep vein thrombosis in trauma patients.
Arnold JD; Dart BW; Barker DE; Maxwell RA; Burkholder HC; Mejia VA; Smith PW; Longley JM
Am Surg; 2010 Jun; 76(6):563-70. PubMed ID: 20583509
[TBL] [Abstract][Full Text] [Related]
53. Assessment of HIT antibody complex in hip fracture patients receiving enoxaparin or unfractionated heparin.
Griffin JW; Hopkinson WJ; Lassen MR; Thethi I; Litinas E; Fareed J
Clin Appl Thromb Hemost; 2011; 17(6):567-71. PubMed ID: 22345625
[TBL] [Abstract][Full Text] [Related]
54. Deep venous thrombosis prophylaxis in trauma: cost analysis.
Wade WE; Chisholm MA
Blood Coagul Fibrinolysis; 2000 Jan; 11(1):101-6. PubMed ID: 10691104
[TBL] [Abstract][Full Text] [Related]
55. Extended-duration low-molecular-weight heparin prophylaxis following total joint arthroplasty.
Whang PG; Lieberman JR
Am J Orthop (Belle Mead NJ); 2002 Sep; 31(9 Suppl):31-6. PubMed ID: 12349893
[TBL] [Abstract][Full Text] [Related]
56. [Chronicity of hypercoagulative state: a favourable evidence for postoperative prolongation of antithrombotic prophylaxis].
Iturbe Hernández T; Cornudella Lacasa R; Moreno Chulilla JA; Gutiérrez Martín M
Med Clin (Barc); 2003 Apr; 120(14):559. PubMed ID: 12724070
[No Abstract] [Full Text] [Related]
57. Enoxaparin: the low-molecular-weight heparin for prevention of postoperative thromboembolic complications.
Carter CA; Skoutakis VA; Spiro TE; West ME; Tooms RE; Joe RH; Knutson TJ
Ann Pharmacother; 1993 Oct; 27(10):1223-30. PubMed ID: 8251693
[TBL] [Abstract][Full Text] [Related]
58. Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism.
Lefebvre P; Coleman CI; Bookhart BK; Wang ST; Mody SH; Tran KN; Zhuo DY; Huynh L; Nutescu EA
J Med Econ; 2014 Jan; 17(1):52-64. PubMed ID: 24156243
[TBL] [Abstract][Full Text] [Related]
59. Enoxaparin for thromboprophylaxis in morbidly obese patients undergoing bariatric surgery: findings of the prophylaxis against VTE outcomes in bariatric surgery patients receiving enoxaparin (PROBE) study.
Hamad GG; Choban PS
Obes Surg; 2005; 15(10):1368-74. PubMed ID: 16354513
[TBL] [Abstract][Full Text] [Related]
60. Review of fondaparinux sodium injection for the prevention of venous thromboembolism in patients undergoing surgery.
Bergqvist D
Vasc Health Risk Manag; 2006; 2(4):365-70. PubMed ID: 17323590
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
